In the past decade, the Chinese vaccine market tripled in scale. China has already become the world's largest vaccine producer and now has 28 vaccine companies, ranking number.1 around the globe, according to a new report added to the offerings of Reportlinker.
The country can now produce one billion person-portions annually, besides, varieties and quantity also ranks the top in the world. Output of common vaccines, such as HBV vaccine, measles vaccine, etc, has reached 500 million person-portions, and fully-planned immunization has been realized, the report notes.
Compared to developed countries, China's expenditures on vaccine and diseases treatment are relatively low; therefore, China will attach great importance to vaccine industry development and take it as the key of health care and biotechnology industry. The Development Strategy of China Biotechnology Industry has rendered the development of secure new types of vaccines as priority.
In the meantime, the Chinese government has employed preferential taxation policy to this industry. In consequence, the vaccine industry will become a high-tech sector with great potential in China biotechnology field. It is forecast that China's vaccine market scale will approximate 8 billion renminbi ($1.78 billion) in 2020, with an annual growth rate of 15%, far above world's level 10%.the report notes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze